Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice …
…, DF McDermott, A Naing, LJ Nastoupil… - Journal of clinical …, 2018 - ascopubs.org
Purpose To increase awareness, outline strategies, and offer guidance on the recommended
management of immune-related adverse events in patients treated with immune …
management of immune-related adverse events in patients treated with immune …
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update
PURPOSE To increase awareness, outline strategies, and offer guidance on the recommended
management of immune-related adverse events (irAEs) in patients treated with immune …
management of immune-related adverse events (irAEs) in patients treated with immune …
[HTML][HTML] Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium
LJ Nastoupil, MD Jain, L Feng, JY Spiegel… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE Axicabtagene ciloleucel (axi-cel) is an autologous CD19-directed chimeric antigen
receptor (CAR) T-cell therapy approved for relapsed/refractory large B-cell lymphoma (…
receptor (CAR) T-cell therapy approved for relapsed/refractory large B-cell lymphoma (…
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
…, PJ Ho, JA Pérez-Simón, AI Chen, LJ Nastoupil… - Nature medicine, 2022 - nature.com
Tisagenlecleucel is an autologous anti-CD19 chimeric antigen receptor-T cell therapy with
clinically meaningful outcomes demonstrated in patients with relapsed/refractory (r/r) B-cell …
clinically meaningful outcomes demonstrated in patients with relapsed/refractory (r/r) B-cell …
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
…, LJ Nastoupil, N Fowler, R Eric Davis, J Westin… - Nature medicine, 2020 - nature.com
Autologous chimeric antigen receptor (CAR) T cell therapies targeting CD19 have high
efficacy in large B cell lymphomas (LBCLs), but long-term remissions are observed in less than …
efficacy in large B cell lymphomas (LBCLs), but long-term remissions are observed in less than …
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
…, LJ Nastoupil, J Westin, R Arora, ML Wang, J Turner… - Nature medicine, 2023 - nature.com
Increasing evidence suggests that the gut microbiome may modulate the efficacy of cancer
immunotherapy. In a B cell lymphoma patient cohort from five centers in Germany and the …
immunotherapy. In a B cell lymphoma patient cohort from five centers in Germany and the …
Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study
PURPOSE Mosunetuzumab is a bispecific antibody targeting CD20 and CD3 that redirects
T cells to engage and eliminate malignant B cells and is being developed for relapsed or …
T cells to engage and eliminate malignant B cells and is being developed for relapsed or …
[PDF][PDF] Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update
…, DK Hawley, AA Langston, LJ Nastoupil… - Journal of Clinical …, 2018 - canhgiacduoc.org.vn
… Nastoupil and Kenneth V. Rolston, MD Anderson Cancer Center, Houston, TX; Michelle
Rajotte, The Leukemia and Lymphoma Society, Rye Brook, NY; and Lynne Strasfeld …
Rajotte, The Leukemia and Lymphoma Society, Rye Brook, NY; and Lynne Strasfeld …
[HTML][HTML] Complete surgical excision is essential for the management of patients with breast implant–associated anaplastic large-cell lymphoma
…, CM McCarthy, SE Hanson, LJ Nastoupil… - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
Purpose Breast implant–associated anaplastic large-cell lymphoma (BI-ALCL) is a rare type
of T-cell lymphoma that arises around breast implants. The optimal management of this …
of T-cell lymphoma that arises around breast implants. The optimal management of this …
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
L Amini, SK Silbert, SL Maude, LJ Nastoupil… - Nature Reviews …, 2022 - nature.com
Chimeric antigen receptor (CAR) T cells have emerged as a potent therapeutic approach for
patients with certain haematological cancers, with multiple CAR T cell products currently …
patients with certain haematological cancers, with multiple CAR T cell products currently …